CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions

Pharmacogenomics

Volumn 14, Issue 10, 2013, Pages 1191-1201

  Kuo, Hsiang Wei ^a,b,c   Liu, Shu Chih ^a,b,c   Tsou, Hsiao Hui ^a,b,c   Liu, Sheng Wen ^a,b,c   Lin, Keh Ming ^a,b,c   Lu, Shao Chun ^a,b,c   Hsiao, Mei Chun ^a,b,c   Hsiao, Chin Fu ^a,b,c   Liu, Chia Yih ^a,b,c   Chen, Chia Hui ^a,b,c   Lu, Mong Liang ^a,b,c   Shen, Winston W ^a,b,c   Tang, Hwa Sheng ^a,b,c   Liu, Shen Ing ^a,b,c   Chang, Liang Huey ^a,b,c   Wu, Hsiao Yu ^a,b,c   Chang, Yao Sheng ^a,b,c   Yeh, Teng Kuang ^a,b,c   Chen, Andrew Ch ^a,b,c   Liu, Yu Li ^a,b,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CYP1A2; escitalopram; major depressive disorder; side effects; SNP

Indexed keywords

CYTOCHROME P450 1A2; DINORCITALOPRAM; DRUG METABOLITE; ESCITALOPRAM; NORCITALOPRAM; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADVERSE OUTCOME; ALLELE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; CONTROLLED STUDY; CYP1A2 GENE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HAPLOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PATIENT COMPLIANCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VOMITING; XEROSTOMIA; ADVERSE DRUG REACTION; DEPRESSIVE DISORDER, MAJOR; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PATHOLOGY;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; CYTOCHROME P-450 CYP1A2; DEPRESSIVE DISORDER, MAJOR; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84880485709     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.105     Document Type: Article

References (38)

1. Chien IC, Kuo CC, Bih SH et al. The prevalence and incidence of treated major depressive disorder among National Health Insurance enrollees in Taiwan, 1996 to 2003. Can. J. Psychiatry 52(1), 28-36 (2007).
2. Angst J, Gamma A, Endrass JRM et al. Is the association of alcohol use disorders with major depressive disorder a consequence of undiagnosed bipolar-II disorder? Eur. Arch. Psychiatry Clin. Neurosci. 256(7), 452-457 (2006). (Pubitemid 44584062)
3. Rao N. The clinical pharmacokinetics of escitalopram. Clin. Pharmacokinet. 46(4), 281-290 (2007). (Pubitemid 46507007)
4. Burke WJ. Escitalopram. Expert Opin. Investig. Drugs 11(10), 1477-1486 (2002). (Pubitemid 35174942)
5. Von Moltke L, Greenblatt D, Giancarlo G, Granda B, Harmatz J, Shader R. Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. 29(8), 1102-1109 (2001). (Pubitemid 32660528)
6. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich F. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270(1), 414-423 (1994). (Pubitemid 24229655)
7. Palatini P, Ceolotto G, Ragazzo F et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J. Hypertens. 27(8), 1594-1601 (2009).
8. Laika B, Leucht S, Heres S, Schneider H, Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2.*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J. 10(1), 20-29 (2010).
9. Zhang WV, D'Esposito F, Edwards RJ, Ramzan I, Murray M. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metab. Dispos. 36(12), 2547-2555 (2008).
10. Liu H, Hu Y, Liu Y, He Y, Li W, Yang L. CYP1A2 is the major isoform responsible for paeonol O-demethylation in human liver microsomes. Xenobiotica 39(9), 672-679 (2009).
11. Gunes A, Ozbey G, Vural Eh et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 10(5), 769-778 (2009).
12. Ghahramani P, Ellis S, Lennard M, Ramsay L, Tucker G. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br. J. Clin. Pharmacol. 43(2), 137-144 (1997). (Pubitemid 27085364)
13. Nielsen K, Flinois J, Beaune P, Brosen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J. Pharmacol. Exp. Ther. 277(3), 1659-1664 (1996). (Pubitemid 27167184)
14. Spina E, Pollicino A, Avenoso A, Campo G, Perucca E, Caputi A. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther. Drug Monit. 15(3), 243-246 (1993). (Pubitemid 23171910)
15. Skinner M, Kuan HY, Pan A et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther. 73(3), 170-177 (2003). (Pubitemid 36269668)
16. Stormer E, Von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab. Dispos. 28(10), 1168-1175 (2000).
17. Dorado P, Berecz R, Penas-Lledo EM, De La Rubia A, Llerena A. No effect of the CYP1A2.*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. Eur. J. Clin. Pharmacol. 63(5), 527-528 (2007). (Pubitemid 46569928)
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (4th Edition, Text Revision). American Psychiatric Association, Washington, DC, USA (2000).
19. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6(4), 278-296 (1967).
20. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56-62 (1960).
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, USA (1976).
22. Riedel M, Moller H, Obermeier M et al. Response and remission criteria in major depression - a validation of current practice. J. Psychiatr. Res. 44(15), 1063-1068 (2010).
23. McGahuey C, Gelemberg A, Laukes C et al. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J. Sex Marital Ther. 26, 25-40 (2000). (Pubitemid 30046590)
24. Kristoffersen L, Bugge A, Lundanes E, Slordal L. Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fluorescence detection. J. Chromatogr. B. Biomed. Sci. App. 734(2), 229-246 (1999).
25. Tsai MH, Lin KM, Hsiao MC et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11(4), 537-546 (2010).
26. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 73(1), 13-22 (1986).
27. Barrett J, Fry B, Maller J, Daly M. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005). (Pubitemid 40202029)
28. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 70(2), 425-434 (2002). (Pubitemid 34112296)
29. Jia Y, Yu X, Zhang B et al. No association between polymorphisms in three genes of cytochrome p450 family and paranoid schizophrenia in northern Chinese Han population. Eur. Psychiatry 19(6), 374-376 (2004). (Pubitemid 39207966)
30. Sun P, Qian J, Zhang ZB et al. Polymorphisms in phase I and phase II metabolism genes and risk of chronic benzene poisoning in a Chinese occupational population. Carcinogenesis 29(12), 2325-2329 (2008).
31. Yuan HY, Chiou JJ, Tseng WH et al. FASTSNP: An always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 34(Web Server issue), W635-W641 (2006).
32. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 296(5576), 2225-2229 (2002). (Pubitemid 34680308)
33. Schrenk D, Brockmeier D, Morike K, Bock K, Eichelbaum M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur. J. Clin. Pharmacol. 53(5), 361-367 (1998). (Pubitemid 28067979)
34. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C→ A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47(4), 445-449 (1999). (Pubitemid 29161279)
35. Chen X, Wang L, Zhi L et al. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin. Pharmacol. Ther. 78(3), 249-259 (2005). (Pubitemid 41254110)
36. Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 11(3), 481-494 (2009).
37. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev. 42(2), 268-354 (2009).
38. Takeuchi DT, Chung RC, Lin KM et al. Lifetime and twelve-month prevalence rates of major depressive episodes and dysthymia among Chinese Americans in Los Angeles. Am. J. Psychiatry 155(10), 1407-1414 (1998).(Pubitemid 28471198)